CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.

PLoS One · 2014 · PMC4006838 · PMID 24788118

Europe PMC DOI

hedged sentences

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

showed a trendp = 0.053so close (0.05 < p ≤ 0.1)

In analyses of the correlation of mutation status of CTNNB1 and efficacy of meloxicam treatment, mutation status showed a trend to associate with efficacy (p = 0.053, Table 2 ).

also in 53,322 other papers

failed to reach statistical significanceno p-value reported

showed that 2-year recurrence rates in mutated tumors (64%) were slightly worse than those in wild-type (77%), although the difference failed to reach statistical significance [32] .

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.